阿帕替尼联合吉西他滨和顺铂方案治疗驱动基因阴性非小细胞肺癌的效果

目的探讨阿帕替尼联合吉西他滨和顺铂(GP方案)治疗驱动基因阴性非小细胞肺癌的效果。方法选取2018年1月至2018年10月间伊犁州奎屯医院收治的68例驱动基因阴性非小细胞肺癌患者,按照治疗方案不同进行分组,其中,采用GP方案治疗的32例患者纳入对照组,在GP方案基础上加用阿帕替尼治疗的36例患者纳入研究组。比较两组患者近期疗效、治疗前后肿瘤标志物水平、生活质量评分和KPS评分、生存情况及不良反应发生率。结果观察组患者总缓解率及疾病控制率均高于对照组患者,差异均有统计学意义(均P<0.05)。治疗前,两组患者癌胚抗原(CEA)及血管内皮细胞因子(VEGF)水平比较,差异无统计学意义(P>0.05)。治疗后,两组患者上述评分均较治疗前降低,观察组患者上述因子水平均低于对照组患者,差异均有统计学意义(均P<0.05)。治疗前,两组患者健康调查简表(SF-36)及卡氏评分(KPS)比较,差异无统计学意义(P>0.05)。治疗后,两组患者上述评分均较治疗前提升,且观察组患者上述评分高于对照组患者,差异均有统计学意义(均P<0.05)。观察组患者中位生存时间为(11.09±1.98)个月,对照组患者中位生存时间为(9.11±1.01)个月,差异有统计学意义(P<0.05)。观察组患者1年生存率为38.9%,对照组患者为34.4%,差异无统计学意义(P>0.05)。观察组患者各类治疗不良反应发生率为74.3%,对照组为68.8%,差异无统计学意义(P>0.05)。结论阿帕替尼联合GP方案对驱动基因阴性非小细胞肺癌患者具有较好的治疗效果,能够降低患者肿瘤因子水平,提高生活质量,延长生存时间。

Efficacy of apatinib combined with gemcitabine and cisplatin in the treatment of driver gene-negative non-small cell lung cancer

Objective To explore the effect of apatinib combined with gemcitabine and cisplatin(GP regimen)in the treatment of driver gene-negative non-small cell lung cancer.Methods Sixty-eight patients with driver gene-negative non-small cell lung cancer who were treated at Kuitun Hospital from January 2018 to October 2018 were selected as study subjects.They were divided into an experimental group(36 patients)and a control group(32 patients).Patients in the experimental group were treated with apatinib combined with GP regimen.Patients in the control group received GP regimen.The short-term efficacy,tumor marker levels and quality of life before and after treatment as well as Karnofsky performance scale(KPS)score were compared between the two groups.The survival and incidence of adverse reactions were also compared between the two groups.Results The overall response rate and disease control rate were significantly higher in the experimental group than in the control group(all P<0.05).There was no statistically significant difference in the levels of carcinoembryonic antigen(CEA)and vascular endothelial growth factor(VEGF)between the two groups of patients before treatment(P>0.05).After the treatment,VEGF and CEA levels decreased in both groups with the experimental group lower than the control group(all P<0.05).Before the treatment,the difference in the MOS item short from health survey(SF-36)and KPS scores was not statistically significant between the two groups(P>0.05),and the SF-36 and KPS scores increased in both groups after the treatment with the experimental group higher than the control group(all P<0.05).The median survival time was 11.09±1.98 months in the experimental group which was higher than 9.11±1.01 of the control group(P<0.05).The 1-year survival rate was 38.9%in the experimental group and 34.4%in the control group(P>0.05).The difference in the incidence of adverse reactions was not statistically significant between the two groups(74.3%vs.68.8%,P>0.05).Conclusion Apatinib combined with GP regimen has a good therapeutic efficacy for driver-negative non-small cell lung cancer,which can significantly reduce tumor factor levels,improve quality of life and extend survival time.